797-P: Impact of Carbohydrate Counting on Glycaemic Control in People with Type 1 and Type 2 Diabetes on Intensified Insulin Therapy

This study involved 154 subjects with type 1 and type 2 diabetes (84.6% with type 1 diabetes, age 46.6 ±13.6 years; 52% female, A1c 8.3 ± 0.9 %) who were undergoing intensified insulin therapy. Participants completed a questionnaire (SMART) that measures the accuracy of estimating carbohydrates in 27 foods or in meals, using the multiple-choice method. At the same time, glucose data collected by a flash glucose monitoring system were analysed in the two weeks prior to completion of the SMART questionnaire. The level of estimation error regarding carbohydrates correlated significantly with glucose variability (CV; r=-0.29; p 180 mg/dl; r=0.015, p=0.843) or hypoglycemic phases ( Disclosure N. Hermanns: Advisory Panel; Self; Roche Diabetes Care. Research Support; Self; Abbott, AstraZeneca, Berlin-Chemie AG. D. Ehrmann: Speaker’s Bureau; Self; Abbott, Berlin-Chemie AG, Glooko, Inc. Other Relationship; Self; Dexcom, Inc., Roche Diabetes Care. B. Kulzer: Research Support; Self; Abbott, AstraZeneca, Berlin-Chemie AG, Roche Diabetes Care. Speaker’s Bureau; Self; Abbott, Ascensia Diabetes Care, Berlin-Chemie AG, Eli Lilly and Company, Medtronic, Novo Nordisk Inc., Roche Diabetes Care. Funding Abbott Diabetes Care Germany